Polymorphisms in dipeptidyl peptidase IV gene are associated with the risk of myocardial infarction in patients with atherosclerosis

Neuropeptides

Volumn 46, Issue 6, 2012, Pages 367-371

  Aghili, Nima ^a   Devaney, Joseph M ^b   Alderman, Lee O ^b   Zukowska, Zofia ^c   Epstein, Stephen E ^b   Burnett, Mary Susan ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

DPP IV; Genetic polymorphism; Myocardial infarction; SNP

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ATHEROSCLEROSIS; COHORT STUDIES; CORONARY ARTERY DISEASE; DIPEPTIDYL PEPTIDASE 4; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ARRAY ANALYSIS; RISK;

EID: 84869873926     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.10.001     Document Type: Article

References (27)

1. Ansorge S., Bank U., Heimburg A., Helmuth M., Koch G., Tadje J., Lendeckel U., Wolke C., Neubert K., Faust J., Fuchs P., Reinhold D., Thielitz A., Tager M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPPIV) and aminopeptidase N (APN) families in immune functions. Clin. Chem. Lab. Med. 2009, 47:253-261.
2. Arbustini E., Dal Bello B., Morbini P., Burke A., Bocciarelli M., Specchia G., Virmani R. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999, 82:269-272.
3. Armstrong P.W., Fu Y., Chang W.C. Acute coronary syndromes in the GUSTO-II b trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb investigators. Circulation 1998, 98:1860.
4. Cordero O.J., Salgado F.J., Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 2009, 58:1723-1747.
5. Davies M. The pathophysiology of acute coronary syndrome. Heart 2000, 83:361-366.
6. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br. Heart J. 1983, 50:127-134.
7. Feron D., Begu-Le Corroller A., Piot J.M., Frelicot C., Vialettes B., Fruitier-Arnaudin I. Significant lower VVH7-like immunoreactivity serum level in diabetic patients: evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP-IV. Peptides 2009, 30(2):256-261.
8. Finn A.V., Nakano M., Narula J., Kolodgie F.D., Virmani R. Concept of vulnerable/unstable plaque. Arterioscler. Thromb. Vasc. Biol. 2010, 30(7):1282-1292. (Review).
9. Fisher M., Blumenfeld A.M., Smith T.W. The importance of carotid artery plaque disruption and hemorrhage. Arch. Neurol. 1987, 44:1086-1089.
10. Kathiresan S. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 2009, 41(3):334-341. Myocardial Infarction Genetics Consortium Authors.
11. Law M.R., Watt H.C., Wald N.J. The underlying risk of death after myocardial infarction in the absence of treatment. Arch. Intern. Med. 2002, 162:2405.
12. Li L., Najafi A.H., Kitlinska J.B., Neville R., Laredo J., Epstein S.E., Burnett M.S., Zukowska Z. Of mice and men: Neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability. J. Cardiovasc. Transl. Res. 2011, 4(3):351-362.
13. McKillop A.M., Duffy N.A., Lindsay J.R., O'Harte F.P.M., Bell P.M., Flatt P.R. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res. Clin. Pract. 2008, 79:79-85.
14. Mentlein R. Dipeptidyl-peptidase IV (CD26)-Role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85:9-24.
15. Montalescot G., Dallongeville J., Van Belle E. STEMI and NSTEMI: Are they so different? 1year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur. Heart J. 2007, 28:1409.
16. Nagashima M., Watanabe T., Terasaki M., Tomoyasu M., Nohtomi K. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011, 54:2649-2659.
17. Ozyazgan S., Kutluata N., Afsar S., Ozdas S.B., Akkan A.G. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 2005, 74:119-126.
18. Reinhold D., Bank U., Tager M., Ansorge S., Wrenger S., Thielitz A., Lendeckel U., Faust J., Neubert K., Brocke S. DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: Implications for experimental encephalomyelitis and multiple sclerosis. Front. Biosci. 2008, 2356-2363.
19. Reinhold D., Goihl A., Wrenger S., Reinhold A., Kuhlmann U.C., Faust J., Neubert K., Thielitz A., Brocke S., Tager M., Ansorge S., Bank U. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: Investigations in DP IV/CD26-knockout mice. Clin. Chem. Lab. Med. 2009, 47:268-274.
20. Rietzschel E., De Buyzere M. High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. Biomark. Med. 2012, 6(1):19-34.
21. Ryskjaer J., Deacon C., Carr R., Krarup T., Madsbad S., Holst J. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 2006, 155:797-803.
22. Sato Y., Koshioka S., Kirino Y., Kamimoto T., Kawazoe K., Abe S., Minakuchi K., Nakahori Y. Role of dipeptidyl peptidase IV (DPP4) in the development of dyslipidemia: DPP4 contributes to the steroid metabolism pathway. Life Sci. 2011, 88(1-2):43-49.
23. Virmani R., Kolodgie F., Burke A., Farb A., Schwartz S.M. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1262-1275.
24. Virmani R., Kolodgie F., Burke A., Finn A., Gold H., Tulenko T., Wrenn S., Narula J. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis is a source of intraplaque hemorrhage. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2054-2061.
25. Vittone F., Liberman A., Vasic D., Ostertag R., Esser M., Walcher D., Ludwig A., Marx N., Burgmaier M. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012, 55(8):2267-2275.
26. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.T. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 2006, 317:1106-1113.
27. Zukowska-Grojec Z., Pruszczyk P., Colton C., Yao J., Shen G.H., Myers A.K. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 1993, 14(2):263-268.